• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » John Fox

John Fox

Articles

ARTICLES

Transplanted stem cells release dopamine in PD model, study shows

Oct. 29, 2014
By John Fox
HONG KONG – Chinese researchers have demonstrated that grafted neural stem cells directly release dopamine into the damaged striata of rat brains in vivo and partially rescued a model of Parkinson's disease (PD), providing proof of concept for the feasibility of that technique for treating PD in humans.
Read More

Multiple markers predict multipotent mesenchymal stem cells

Oct. 22, 2014
By John Fox
HONG KONG - A multidisciplinary research team from the Singapore-Massachusetts Institute of Technology (MIT) Alliance in Research and Technology (SMART) has identified a unique set of biophysical markers that are predictive for multipotent mesenchymal stromal cells in bone marrow, which should make it easier to develop stem cell-based therapies.
Read More

Multiple markers predict multipotent mesenchymal stem cells

Oct. 20, 2014
By John Fox
HONG KONG - A multidisciplinary research team from the Singapore-Massachusetts Institute of Technology (MIT) Alliance in Research and Technology (SMART) has identified a unique set of biophysical markers that are predictive for multipotent mesenchymal stromal cells in bone marrow, which should make it easier to develop stem cell-based therapies.
Read More

Nanocomplex delivery system boosts cancer drug efficacy, safety

Oct. 15, 2014
By John Fox
HONG KONG – Scientists from the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) in Singapore have used an antioxidant extract of green tea to engineer a cancer drug nanocarrier system, which can deliver drugs to kill cancer cells more effectively, while minimizing toxicity to surrounding tissues.
Read More

Nanocomplex delivery system boosts cancer drug efficacy, safety

Oct. 14, 2014
By John Fox
HONG KONG – Scientists from the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) in Singapore have used an antioxidant extract of green tea to engineer a cancer drug nanocarrier system, which can deliver drugs to kill cancer cells more effectively, while minimizing toxicity to surrounding tissues.
Read More

Crucial new therapeutic target identified in multiple myeloma

Oct. 8, 2014
By John Fox
HONG KONG – Japanese scientists have identified a potent cell signaling mediator that could represent an important universal therapeutic target molecule for the development of effective new treatments for multiple myeloma (MM).
Read More

Crucial new therapeutic target identified in multiple myeloma

Oct. 7, 2014
By John Fox
HONG KONG – Japanese scientists have identified a potent cell signaling mediator that could represent an important universal therapeutic target molecule for the development of effective new treatments for multiple myeloma (MM).
Read More

Chinese researchers find promising new target for obesity drugs

Oct. 1, 2014
By John Fox
HONG KONG - For the first time, Chinese scientists have identified the molecular mechanism underlying the anorexogenic effects of a safe and effective herbal dietary supplement that is widely used for weight control, providing a promising target for the development of novel obesity drugs.
Read More

Chinese researchers find promising new target for obesity drugs

Oct. 1, 2014
By John Fox
HONG KONG - For the first time, Chinese scientists have identified the molecular mechanism underlying the anorexogenic effects of a safe and effective herbal dietary supplement that is widely used for weight control, providing a promising target for the development of novel obesity drugs.
Read More

Small molecule a promising lead candidate for new HCC therapy

Sep. 24, 2014
By John Fox
HONG KONG - Researchers from the Chinese University of Hong Kong (CUHK) have identified a small-molecule compound that dramatically inhibited tumor growth in a mouse model of hepatocellular carcinoma (HCC), representing a promising lead candidate for further investigation as an urgently needed new class of HCC therapy.
Read More
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2025.
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe